Since only a small proportion of biotherapeutics that enter clinical trials make it to reach the market, companies tend to have a large pipeline of candidates, like monoclonal antibodies (mAbs) or gene therapy. This implies that there are many processes that need to be developed at the same time. In addition, pressure from healthcare providers is driving the need to reduce the manufacturing costs. Therefore, upstream and downstream optimization is necessary. The Bioprocessing of Biologics like m...

The continuous emergence of SARS-CoV-2 variants has highlighted the global need to immunize the population. For this reason, the STABVAC4COV project aims to develop a vaccine against the Delta variant of SARS-CoV-2 that is more stable than the current ones and, consequently, easier to distribute. mRNA technology will be used for its development. In parallel, the proyect will work on the development of compounds, especially enzymes involved in the RNA synthesis process in vitro. With this kno...

In recent years, there has been a notable increase in the number of therapeutic molecules. This increase has led to a corresponding increase in the number of CDMOs like us. With so many CDMOs to choose from, it is crucial for biopharmaceutical companies to carefully consider their selection criteria.   Finding the Right Biologics CDMO Partner  To ensure that you select the right biologics CDMO partner for your project, it’s important to ask yourself: Will you be working with the CDMO...

53Biologics participates in the OLIGOFASTX project. This project aims to create a comprehensive platform to facilitate and contribute to the accelerated development of oligonucleotide-based therapies in Spain. OLIGOFASTX is a multidisciplinary consortium led by Sylentis (PharmaMar Group) and in which other companies such as Nanovex Biotechnologies, ARTHEx Biotech, Aptus Data Labs, aptaTargets and Nostrum Biodiscovery participate in addition to 53Biologics. 53Biologics participates in th...

So to decide which is the best option in medicine and biopharma between biologics or small molecule drugs, we have to consider many factors. But let´s start from the beginning.  What Is a Small Molecule Drug?  Small molecule drugs are typically derived from natural compounds produced by plants, fungi and bacteria or are designed to imitate them. These drugs use biochemical processes to prevent or treat diseases. They are highly effective as allosteric modulators and enzyme inhibitors, and are...

The rapidly growing market for biologics has made contract biologics development and production corporations (CDMO) more essential. The complexity inherent in the development of biologics and their mass production for sale makes it impossible for biopharmaceutical and pharmaceutical companies to perform the process in-house. What Is a Biologics CDMO Company?  A contract biologics development and manufacturing company (CDMO) provides medical biologics development and manufacturing services for p...

In today’s pharmaceutical and biotechnology industry, the focus is on reducing development time and obtaining faster approval for high-quality therapies. However, biologics present unique and time-consuming challenges, such as cell line and analytical development, biological instability, scale-up and limited capacity, which can negatively impact time to market and financial results. Here are 5 steps to create a successful strategy that will help accelerate the time to a robust and reliable...